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Abstract
Background-The development of a re-
producible, sensitive, and standardised
human papillomavirus (HPV) polymerase
chain reaction (PCR) test is required to
implement HPV testing in cervical cancer
screening programmes and for triaging
women with mild to moderate dysplasia.
Aims-To determine the intermethod
agreement between different GP5+/6+ and
MY09/11 PCR based protocols for the
detection and typing of high risk (HR)
HPV DNA in cervical smears and to
assess the intramethod reproducibility of
the GP5+/6+ PCR enzyme immunoassay
(EIA) for HR-HPV detection.
Methods-For the intermethod compari-
son, crude aliquots of 20 well character-
ised cervical smears comprising five HPV
negative samples, and six and nine sam-
ples containing single and multiple HPV
infections, respectively, were coded and
sent from reference laboratory (A) to
three other laboratories. One of these
(laboratory B) used the GP5+16+ PCR-
EIA and was provided with standard pro-
tocols. Another laboratory (C) used
GP5+/6+ PCR combined with sequence
analysis and type specific PCR, whereas
two laboratories (D and E) used MY09/11
PCR followed by restriction fragment
length polymorphism (RFLP) analysis for
the detection and typing of HR-HPV. The
intramethod agreement of GP5+/6+ PCR-
EIA was analysed in a subsequent study
with four other laboratories (F to I) on
crude aliquots of 50 well characterised
cervical smears, consisting of 32 HR-HPV
positive and 18 HPV negative samples.
Standardised protocols, primers, and
probes were also provided by the refer-
ence laboratory for HR-HPV detection.
Results-In the intermethod comparison,
pairwise agreement of the different labo-
ratories with reference laboratory A for
the detection of HR-HPV varied between
75% and 100% (K values: 0.5 to 1). Typing
data revealed a broader range in pairwise
agreement rates between 32% and 100%.
The highest agreement was found between
laboratories A and B using standardised
protocols and validated reagents. In the
intramethod evaluation, pairwise com-
parison of the laboratories F to I with ref-
erence laboratory A revealed excellent
agreement rates from 92% to 100% (K
values: 0.88 to 1.0) with an overall sensitiv-
ity of 97.5% (195/200) and specificity of
99.5% (199/200).
Conclusions-The detection of HR-HPV
as a group is highly reproducible with
GP5+/6+ PCR-EIA provided that stand-
ardised protocols and validated reagents
are used.
(J Clin Pathol 1999;52:498-503)
Keywords: human papillomavirus; polymerase chain
reaction; intermethod agreement; intramethod
agreement
Worldwide, cervical cancer is one of the most
common forms of cancer among women.
Although cytomorphological screening of cer-
vical smears (the Papanicolaou test) has
reduced the incidence of cervical cancer
significantly, the test still has some limitations
with respect to sensitivity and specificity. False
negative rates for cervical premalignant lesions
and cervical cancer between 15% and 50% and
false positive rates of about 30% have been
reported.`
To date, it has been shown that high risk
human papillomavirus (HR-HPV) genotypes
are implicated in the aetiology of cervical
cancer.4 Consequently, the inclusion of HR-
HPV testing in cervical cancer screening
programmes and the triaging of women with
mild to moderate cervical dysplasia has been
advocated.5
As HPV cannot be cultured in vitro and no
suitable serological assays are at present
available, current methods are based on the
detection of HPV DNA in exfoliated cervical
cells. These methods include the hybrid
capture assay (HCA), a simple direct HPV
DNA detection assay using signal
amplification,9 and the polymerase chain reac-
tion (PCR) which is based on the in vitro
amplification of target sequences.'" Both ap-
proaches seem robust and potentially suitable
for routine. Concerning the PCR based meth-
ods, HPV type specific PCR are not suitable for
large clinical trials owing to the wide variety of
HPV genotypes infecting the genital tract.
Broad spectrum detection has therefore been
facilitated by consensus PCR assays, with gen-
eral primers selected from highly conserved
sequences of the majority of mucosal HPV
genotypes. '1-4 Moreover, subsequent detection
steps are continuously amenable to modifica-
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tions to render these general primer PCR
assays more feasible for large numbers of sam-
ples.
In order to consider HPV testing for cervical
cancer screening programmes, issues like the
reproducibility between different HPV meth-
ods and between different testing centres need
further attention. The reproducibility of both
HCA and the widely used general primer
MYO9/1 1 mediated PCR assay using different
read-out protocols has already been
evaluated.'5-17 Recently, the read-out system of
another widely used general primer mediated
PCR system, the GP5+/6+ PCR, has been
converted from conventional radioactive
Southern blot hybridisation of the PCR
products in a colorimetric enzyme immu-
noassay (EIA) (GP5+/6+ PCR-EIA).'8 Like
the latest version of HCA,'9 it is a non-
radioactive detection procedure in microtitre
plate format which is easy to perform and gen-
erates objective numerical data. Although this
new GP5+/6+ PCR-EIA system has already
been evaluated on clinical specimens,20 no
interlaboratory reproducibility rates are yet
available. We therefore assessed the reproduc-
ibility of the GP5+/6+ PCR-EIA in a multicen-
tre intermethod and intramethod evaluation.
The results of these evaluations are presented
in this paper.
Methods
SELECTION OF REFERENCE SAMPLES AND
COMPOSITION OF TEST PANELS
Cervical smears were selected from a group of
women with abnormal cervical cytology
(,o mild dysplasia) attending the outpatient
clinics of the University Hospital Vrije Univer-
siteit in Amsterdam, The Netherlands. The
cervical smears were pretreated as described
before."0 Selection of study samples was based
on the following criteria:
(1) an adequate quality of the DNA for PCR
amplification as determined by a PCR
assay with primers spanning 509 base pairs
of the globin gene2";
(2) the presence or absence ofHPV DNA after
GP5+/6+ PCR;
(3) confirmation of HPV types by both
GP5+/6+ PCR-EIA using HR-HPV oligo
(cocktail) probes'9 and HPV E7 type
specific PCR assays22;
(4) samples comprised one or more of the fol-
lowing HPV types considered as high risk:
HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66, and 68.
Fifty cervical smears were selected consisting
of 18 HPV negative and 32 HPV positive sam-
ples. The 32 HPV positive smears comprised
23 single and nine multiple HPV infections.
For the intermethod comparison study, a
subset of the 50 selected cervical smears was
used to prepare a test panel of 20 specimens
consisting of five HPV negative samples and six
and nine samples containing a single and mul-
tiple HPV infections, respectively. The HPV
positive samples comprised together a diversity
of 13 HR-HPV genotypes (HPV 16, 18, 31, 33,
35, 39, 45, 51, 52, 58, 59, 66, and 68).
The test panel for the intramethod compari-
son study consisted of all 50 selected cervical
smears including the 13 different HR-HPV
genotypes and in addition HR-HPV 56.
STUDY DESIGN
One laboratory served as the reference labora-
tory (A) and established the test panel of cervi-
cal smears. Aliquots of these specimens (50 ,ul)
were coded and distributed by laboratory A to
different laboratories. In the test panels, the
HPV negative samples were randomly divided
between the HPV positive samples; 10 gl of the
study samples had to be used for HPV testing.
All participating laboratories had experience
with HPV PCR technology. The reference
laboratory did not participate in the HPV test-
ing but collected and compared the HPV PCR
test results from the different laboratories with
its own reference data. The GP5+/6+ PCR-
EIA results from the reference laboratory (A)
were used as the gold standard as these results
were confirmed by an alternative HPV E7
TS-PCR system and were therefore considered
conclusive.
INTERMETHOD COMPARISON
Four laboratories (B to E) participated in the
intermethod evaluation for the detection and
typing of HR-HPV in cervical smears. These
four laboratories applied their own in-house
HPV PCR assays.
One of these laboratories (B) used the same
method as the reference laboratory (A)-that
is, GP5+/6+ PCR-EIA with a high risk oligo
cocktail probe for the detection of HR-HPV
and individual oligo probes for HPV typing and
was provided with standardised protocols after
an extensive training period.
Another laboratory (C) applied the
GP5+/6+ PCR followed by agarose gel electro-
phoresis to detect the presence of HPV DNA
and used type specific (TS) PCR for HPV 6,
11, 16, and 18 combined with direct sequence
analysis of GP5+/6+ PCR products in cases of
GP5+/6+ PCR positive and TS-PCR negative
samples for HPV typing.
Two other laboratories (D and E) used
MY09/1 1 primer mediated PCR. The presence
of HPV DNA was analysed by agarose gel
electrophoresis of the MY09/11 generated
PCR products while typing was performed by
restriction fragment length polymorphism
(RFLP) analysis and hybridisation of the
RFLP products with a generic oligonucleotide
probe mixture.
INTRAMETHOD COMPARISON
For the intramethod comparison, four other
laboratories (F to I) without previous experi-
ence with GP5+/6+ PCR-EIA participated in
the studies. The reference laboratory (A)
provided a standard operating procedure,
digoxigenin labelled high risk oligo cocktail
probes, and the GP5+/bioGP6+ primers. The
quality of this material was first validated and a
sensitivity of between 10 and 200 copies of the
HPV genome, depending on the HPV type,
could be attained.'7 Other reagents and equip-
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Table 1 Intermethod agreement between different polymerase chain reaction (PCR)
protocols (B-D) performed in different laboratories and the reference data (A) for the
detection of high risk human papillomaviruses (HR-HPV) in 20 cervical smears
Agreement obtainedfor: % Overall agreement
(No of identical / No
Method pair Positives (n=15) Negatives (n=5) tested) K Statistic
AandB 15 5 100% (20/20) 1
A and C 13 5 90% (18/20) 0.76
AandD 14 5 95% (19/20) 0.88
A and E 10 5 75% (15/20) 0.50
B:GP5+/6+ PCR-EIA using HR (high risk) oligococktail probe for HPV 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, and 68. C: GP5+/6+ PCR and agarose gel electrophoresis. D,E:
MY09/11 PCR and agarose gel electrophoresis.
Table 2 Comparison between different methods and the reference data for typing of high
risk human papillomaviruses (HR-HPV)
Laboratory*
Sample Reference data B C D E
1 Neg Neg Neg Neg Neg
2 Neg Neg Neg Neg Neg
3 Neg Neg Neg Neg Neg
4 Neg Neg Neg Neg Neg
5 Neg Neg Neg Neg Neg
6 18 16,18 18 18 18
7 39 39 Neg 39 Neg
8 51 51 HPV post 51 Neg
9 52 52 52 52 52
10 56 56 56 56 56
11 58 33, 58 58 58 58
Typing agreement compared with
reference data for single HPV
infections: 6/6 (100%) 4/6 (67%) 6/6 (100%) 4/6 (67%)
12 16, 35 16, 35 Neg Neg 16, 61
13 16, 68 16, 68 16 16, 68 16
14 31, 35 31, 35 31 35 31
15 33, 35 33, 35 35 35 Neg
16 33,45 18, 33,45 45 33, 52 Neg
17 33,58 33, 58 33 33 33
18 35, 59 35, 59, 66 59 31 31
19 52, 68 52, 68 68 HPV post Neg
20 31,59, 66 31, 59, 66 66 18 18
Typing agreement per HPV type
compared with reference data for
multiple HPV infections: 19/19 (100%) 8/19 (42%) 6/19 (32%) 4/19 (21%)
Overall typing agreement
compared with reference data: 25/25 (100%) 12/25 (42%) 12/25 (48%) 8/25 (32%)
*Lab B: GP5+/6+ PCR-EIA using individual internal oligoprobes for HPV 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 66, and 68; Lab C: TS-PCR for HPV 6/11, 16, and 18 and direct
sequence analysis of GP5+/6+ PCR products; Lab D, E: restriction fragment length
polymorphism analysis ofMY09/11 PCR products followed by hybridisation with an
oligonucleotide probe mixture.
tThe HPV type could not be identified by the typing procedure used, but the sample contained
HPV DNA after hybridisation of the PCR products with a general HPV probe (method C) or after
agarose gel analysis (method E).
For simplicity of the table, the samples have been sorted according to HPV type.
p Value for differences in typing between single and multiple HPV infections < 0.001 (X', a=0.05)-
ment had to be purchased from their local dis-
tributors.
STATISTICAL ANALYSIS
The intermethod and intramethod agreement
for HR-HPV detection was assessed by pair-
wise comparison of the test results with the ref-
erence data using percentage of agreement and
the kappa (K) statistic. Kc Values express the
proportion of possible agreement beyond
chance. A K estimate of less than 0.4 represents
poor agreement, a K estimate between 0.4 and
0.75 is fair to good agreement, and a K estimate
ofmore than 0.75 is excellent agreement.2" For
HPV typing, the intermethod agreement was
assessed by pairwise comparison of the typing
results with the reference data by the percent-
ages of agreement. The x2 test was used to
indicate significant differences between typing
of single and multiple HPV infections.
Results
INTERMETHOD COMPARISON BETWEEN GP5+/6+
AND MY09/11 PCR BASED PROTOCOLS
HPV detection analysis on cervical smears
Aliquots of 20 well characterised cervical
smears were subjected to different PCR proto-
cols employed in the different laboratories and
compared with the reference data (table 1).
Laboratory B correctly identified all 15 HPV
positive smears and all five HPV negative sam-
ples, resulting in an overall agreement of 100%
(20 of 20). Laboratory C failed to detect two
specimens of the 15 HPV positive samples, but
identified all five HPV negative smears. This
resulted in an overall agreement of 90% (18 of
20). Laboratories D and E correctly identified
all HPV negative samples, but both laborato-
ries failed to identify one and five HPV positive
smears, respectively. This revealed an overall
agreement of 95% (19 of 20) for laboratory D
and 75% (15 of 20) for laboratory E. The K
values ranged from 0.50 for agreement be-
tween laboratories A and E, to 0.76 for labora-
tories A and C, to 0.88 for laboratories A and
D, to 1 for laboratories A and B.
HPV typing analysis on HPV positive cervical
smears
Subsequently, to determine differences in
HPV typing of six single and nine multiple HPV
infections by the different procedures, HPV
positive samples were subjected to typing analy-
sis and results were compared with the reference
data. The results are shown in table 2.
Evaluation of the single HPV infections
showed that laboratory B identified the correct
HPV type in all the six samples (samples 6 to
11). However, in two samples (sample 6 and
1 1) an additional HR-HPV type was detected
compared with the reference data. Laboratory
C detected the correct HR-HPV type in four of
the six single HPV infections (samples 6, 9, 10,
and 11). In one single HPV infection (sample
8) the HR-HPV type (HPV 51) could not be
identified, while the remaining sample (sample
7) was tested HPV DNA negative. Only
laboratoryD identified the correct HPV type in
all the six single HPV infections (samples 6 to
11) whereas laboratory E correctly identified
the HR-HPV type in four of the six single HPV
infections (samples 6, 9, 10, and 11). The two
remaining samples (samples 7 and 8) were
tested HPV DNA negative.
Evaluation of the multiple HPV infections
showed that laboratory B correctly typed the
HR-HPVs present in all the nine samples
(samples 12 to 20). However, in two samples
(samples 16 and 18) an additional HR-HPV
type was detected compared with the reference
data. Only a single HPV type was detected in
all nine multiple HPV infections by laboratory
C. In all these nine cases the HR-HPV type
detected corresponded with one ofthe multiple
HPV types present in the sample according to
the reference data. Laboratory D detected sin-
gle HPV types in five of the nine multiple HPV
infections. In three of these (samples 14, 15,
500
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Table 3 GP5+16+ PCR-EIA results obtained by the
different laboratories for the detection of high risk (HR)
human papillomaviruses (HPV) in 50 cervical smears
compared with the reference data
HR-HPV
Reference
Sample data Lab F Lab G Lab H Lab I
1 - - _ _ _
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
16
16
16
16
16
16
18
18
18
31
33
39
45
51
51
52
52
56
56
58
58
59
59
33, 35
16, 68
33,45
35, 59
52, 68
16, 35
31, 35
33, 58
31, 66,59
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
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+
+
+
+
+
+
+
+
+
+
+
+
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+
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+
PCR-EIA, polymerase chain reaction-enzyme immunoassay.
and 17), the type detected corresponded with
one of the HR-HPV in the sample. In the two
other cases (samples 18 and 20), an HR-HPV
type was found which did not represent one of
the types identified by the reference laboratory.
Two multiple HPV infections were detected
where in one sample (sample 13) the HPV
types were correctly identified and in the other
sample (sample 16) the HPV types were partly
identified. Of the two remaining samples, one
(sample 19) was found HPV positive but could
not be identified, while the other sample was
Table 4 Intramethod agreement between laboratories (E-H) and reference laboratory (A)
for the detection of high risk human papillomaviruses (HR-HPV) as a group in 50
cervical smears by GPS+/6+ PCR-EIA
Agreement obtainedfor: Percent overall
Laboratory agreement
pair Positives (n=32) Negatives (n=18) (n identical/n tested) K Statistic
AandF 32 18 100% (50/50) 1
A and G 31 18 98% (49/50) 0.96
A and H 31 18 98% (49/50) 0.96
Aand I 29 17 92% (46/50) 0.83
PCR-EIA, polymerase chain reaction-enzyme immunoassay.
scored HPV negative (sample 12). Laboratory
E also identified single HPV types in five of the
nine multiple HPV infections (samples 13, 14,
17, 18, and 20). In two of these five cases
(samples 18 and 20), the HPV type did not
correspond with either of the HPV types
present in the sample. One double HPV infec-
tion was found (sample 12) including HPV 61,
which the reference laboratory had not tested
for. The remaining three samples (samples 15,
16, and 19) were tested HPV DNA negative.
Taking the typing data together, the percent-
ages of overall agreement with the reference
laboratorywere 100%, 48%, 48%, and 32% for
the methods employed in laboratories B, C, D,
and E, respectively. Moreover, the typing
agreement of all laboratories together was
significantly higher (p < 0.001) for single HPV
infections (83%; 20/24) than for multiple HPV
infections (49%; 37/76).
INTRAMETHOD COMPARISON OF HR-HPV GP5+/6+
PCR-EIA
Crude cell suspensions of 50 cervical smears
were analysed in different laboratories by
GP5+/6+ PCR-EIA and compared to the
reference data.
As shown in table 3, among the HPV
negative samples, one sample (3) was tested
HR-HPV positive by laboratory I only. Among
the HR-HPV positive samples, four samples
(24, 27, 41, and 47) were tested false negative.
One of these samples (47) was tested HR-HPV
negative by two independent laboratories (H
and I), while the remaining three samples were
scored HR-HPV negative by only one of the
laboratories.
Laboratory F correctly identified all 32 HPV
positive and all 18 HPV negative specimens of
the test panel, while both the laboratories G
and H identified all the HPV negative samples
but failed to identify one HR-HPV positive
sample. Laboratory I correctly identified 29 of
the 32 HPV positive samples and additionally
tested one sample HR-HPV positive among the
18 HPV negative specimens of the test panel.
The percentages of agreement between the dif-
ferent laboratories and the reference laboratory
varied from 92% (46 of 50; laboratory I) to
98% (49 of 50; laboratories G and H) to 100%
(50 of 50; laboratory F). Likewise, K values
ranged from 0.83 to 0.96 to 1 for laboratories I,
G and H, and F, respectively. The results are
summarised in table 4.
Discussion
In view of potential applications of HR-HPV
PCR assays in cervical cancer screening
programmes,'4 the intermethod agreement of
GP5+/6+ and MY09/11 consensus PCR based
protocols was investigated by multiple test cen-
tres. A higher reproducibility for HR-HPV
detection than for HPV typing was found.
Among the different protocols, GP5+/6+ PCR
amplification followed by hybridisation of the
PCR products with a cocktail probe for
HR-HPV types in an EIA format revealed the
highest agreement with the reference data.
Moreover, excellent intramethod agreement
between other test centres was obtained with
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this method in a subsequent study. These data
indicate that HR-HPV GP5+/6+ PCR-EIA has
outstanding reproducibility.
INTERMETHOD COMPARISON
Comparison of different in-house HPV PCR
methods with the reference data showed that
the agreement was fair to excellent (K values:
0.5 to 1) for the detection of HR-HPV DNA in
cervical smears (table 1). A markedly lower
agreement rate (75%) for HPV detection was
observed for laboratory E using MY09/1 1 PCR
and agarose gel analysis compared with other
laboratories (90% to 100%). It has to be noted
that the quality of the DNA in all samples was
appropriate for efficient PCR amplification of
at least 500 base pair fragments. As the
MY09/11 PCR amplifies a shorter fragment of
450 base pairs in the HPV LI open reading
frame, the disagreement cannot simply be
explained by inadequate DNA quality of the
specimens. This is further supported by the
observation that laboratory D, using the same
MY9/11 PCR assay including the read-out
protocol, obtained an excellent agreement
(95%) with the reference data for the detection
of HPV DNA. In addition, the agreement
between both laboratories (D and E) using
MY09/1 1 PCR was only fair (K value: 0.40).
The discrepancies were restricted to false
negative test results. Moreover, since all HPV
positive samples included in the test panel con-
tained high amounts of HPV DNA according
to the optical density values of the reference
data, the false negative test results are also
unlikely to be a result of sampling errors.
Furthermore, a broader range in agreement
was found for HPV typing compared with the
detection of HPV DNA. Moreover, the HPV
typing results varied more strongly for the
multiple infections compared with the single
infections (p < 0.001; table 2). In our study it
was shown that differences in read-out systems
make a large contribution to variations in HPV
typing. Direct sequencing of GP5+/6+ PCR
products apparently failed to identify under-
represented HPV types in the multiple HPV
infections, in contrast to hybridisation of
GP5+/6+PCR products with digoxigenin la-
belled oligo probes in EIA. In addition, this lat-
ter method detected some additional HPV
types compared with the reference laboratory
owing to differences in the interpretation of
weak signals. That variations in HPV typing
may occur using different protocols is further
substantiated by the observation that both
laboratories using the same MY09/11 PCR-
RFLP procedures had a lower detection rate
for multiple HPV infections than the labora-
tory using GP5+/6+ PCR-EIA. However, in
another study,25 the reverse was found when a
similar dot blot procedure was used for HPV
typing of both GP5+/6+ and MY09/11 PCR
products derived from the same series of sam-
ples. These data suggest that the efficiency of
HPV testing by consensus PCR is not only
dependent on the specificity of the primers but
also on the read-out system applied. Moreover,
these results strongly reinforce the need for
standardisation of read-out systems employed
in different laboratories.26
INTRAMETHOD COMPARISON
In the intramethod comparison, the reproduc-
ibility of the HR-HPV GP5+/6+ PCR-EIA-
tested on 50 well characterised specimens-
was fairly uniform among different
laboratories, as shown by the small differences
in the agreement rates (92% to 100%; table 4).
Except for one case, the few observed discrep-
ancies comprised false negative test results of
HPV positive samples (table 3). Nevertheless,
the five false negative test results among a total
of 200 tests in the four laboratories show a high
overall sensitivity of 97.5% (195/200). Like-
wise, the specificity of GP5+/6+ PCR for
HR-HPV detection was excellent. There was
only one single false positive test result
obtained among the 200 tests conducted in the
four laboratories, resulting in an overall specifi-
city of 99.5% (199/200).
Finally, the main goal of this study was the
recognition that HPV testing can be performed
reliably by consensus HPV PCR based proto-
cols and between different testing centres.
Smits et al already showed that agreement
between CPI/II PCR and MY09/1 1 PCR for
the detection of HPV DNA in cervical smears
was excellent (K values between 0.82 and
0.84).27 Moreover, high interlaboratory repro-
ducibilities for the detection ofHPV DNA with
MY09/11 PCR in clinical specimens of about
88% to 97% have been found previously.'6 17
The results of our study are in line with these
reports and suggest that the variation in
HR-HPV detection by different consensus
HPV PCR based protocols can be quite small.
Most importantly, however, testing for HR-
HPV as a group appears to be more reproduc-
ible than testing for individual HPV types.
Since results from recent case-control studies
show that the risk for women of getting cervical
cancer does not differ significantly for the
different HPV genotypes,28 29 individual HPV
typing is unlikely to be more relevant clinically
than HR-HPV group specific testing. With the
data obtained in this study, this argues that
HR-HPV group specific detection should be
the strategy of choice in cervical cancer screen-
ing programmes. It has additionally been
shown that the HR-HPV GP5+/6+ PCR-EIA
has high reproducibility for the detection of
HR-HPVs and can easily be transferred to
other laboratories provided that standardised
protocols and validated reagents are used.
Therefore, this test could be used in large clini-
cal trials. Recently, a trial of 44 000 women was
started to evaluate HR-HPV testing with the
GP5+/6+ PCR-EIA in population based cervi-
cal cancer screening.
We are indebted to Mr R P Pol and Mrs N Fransen-Daalmeijer
for technical assistance. We would like to thank the following
laboratories for their participation: Friedrich Schiller Univer-
sitat, Jena; Universitat zu Koln, Koln; Institut fuir Immunologie,
Pathologie und Molekularbiologie, Hamburg; University Hos-
pital Kiel, Kiel; Universitat Heidelberg, Heidelberg in Germany,
General Hospital, University of Lund, Malmo; Karolinska
Institute, Huddinge University Hospital, Huddinge; University
of Umea, Umea; Academic Hospital, University of Uppsala,
Uppsala in Sweden and the University Hospital Vrije University
in Amsterdam, The Netherlands.
502
Reliable high risk HPVDNA testing by PCR
1 Koss LG. The Papanicolaou test for cervical cancer
detection. A triumph and a tragedy. JAMA 1989;261:737-
43.
2 Giard RWM, Bosman FT. Een normaal uitstrijkje en toch
baarmoederhalskanker? Ned Tijdschr Geneeskd 1992;136:
2311-14.
3 Devessa SS, Young JL, Brinton LA, Fraumeni JF. Recent
trends in cervix uteri cancer. Cancer 1989;64:2184-90.
4 IARC. Monographs on the evaluation of carcinogenic risks
to humans. Human papillomaviruses, vol 64. Lyon: Inter-
national Agency for Research on Cancer, 1995.
5 Meijer CJLM, Rozendaal L, van der Linden JC, et al.
Human papillomavirus testing for primary cervical cancer
screening. In: Franco E, Monsenego J, eds. New develop-
ments in cervical cancer screening and prevention. Oxford:
Blackwell Science, 1997:338-47.
6 Cuzick J, Szarewski A, Terry G, et al. Human papillomavirus
testing in primary cervical cancer screening. Lancet
1995;345:1533-6.
7 Cox JT, Lorincz AT, Schiffman MH, et al. Human papillo-
mavirus testing by hybrid capture appears to be useful in
triaging women with a cytologic diagnosis of atypical
squamous cells of undetermined significance. Am J Obstet
Gynecol 1995;172:946-54.
8 Hatch KD, Schneider A, Abdel Nour MW An evaluation of
human papillomavirus testing for intermediate- and
high-risk types as triage before colposcopy. Am J Obstet
Gynecol 1995;172:1150-7.
9 Lorincz AT. Hybrid capture method for detection ofhuman
papillomavirus DNA in clinical specimens. Papillomavirus
Rep 1996;7:1-5.
10 Walboomers JMM, MV Jacobs, JW van Oostveen, et al.
Detection of genital human papillomavirus infections and
possible clinical implications. In: Gross G, Von Krogh G,
eds. Human papillomavirus infections in dermatovenereology.
Boca Raton: CRC Press, 1997:341-64.
11 Manos MM, Ting Y, Wright DK, et al. Use of polymerase
chain reaction amplification for the detection of genital
human papillomaviruses. Cancer cells 1989;7:209-14.
12 Snijders PJF, van den Brule AJC, Schrijnemakers HFJ, et al.
The use of general primers in the polymerase chain
reaction permits the detection of a broad spectrum of
human papillomavirus types. Jf Gen Virol 1990;71: 173-81.
13 de Roda Husman AM, Walboomers JMM, van den Brule
AJC, et al. The use of general primers GP5 and GP6 elon-
gated at their 3' ends with adjacent highly conserved
sequences improves human papillomavirus detection by
polymerase chain reaction.
_7 Gen Virol 1995;76:1057-62.
14 Smits HL, Tieben LM, Tjongh-A-Hung, et al. Detection
and typing of human papillomaviruses present in fixed and
stained archival cervical smears by a consensus polymerase
chain reaction and direct sequence analysis allow the iden-
tification of a broad spectrum of human papillomavirus
types. J Gen Virol 1992;73:3263-8.
15 Schiffman MH, Kiviat NB, Burk RD, et al. Accuracy and
interlaboratory reliability of human papillomavirus DNA
testing by hybrid capture. J Clin Microbiol 1995;33:545-50.
16 Hsing AW, Burk RD, Liaw K-L et al. Interlaboratory agree-
ment in a polymerase chain reaction-based human papillo-
mavirus DNA assay. Cancer Epidemiol Biomarkers Prev
1996;5:483-4.
17 Kuypers JM, Critchlow CW, Gravitt PE, et al. Comparison
of dot filter, Southern transfer hybridization and polymer-
ase chain reaction amplification for diagnosis of anal
human papillomavirus infection. J Clin Microbiol 1993;31:
1003-6.
18 Jacobs MV, van den Brule AJC, Snijders PJF, et al. A
non-radioactive PCR enzyme immunoassay enables rapid
identification of HPV 16 and 18 in cervical smears after
GP5+/6+ PCR.
_J Med Virol 1996;49:223-9.
19 Lorincz A, Davies PO. The hybrid capture II assay for the
detection of human papillomavirus. In: Monsenego J, ed.
Genital infections and neoplasia. Paris: Eurogin Scientific
Publications, 1998:18-20.
20 Jacobs MV, Snijders PJF, van den Brule AJC, et al. A general
primer GP5+/6+ mediated PCR-enzyme immunoassay
method for rapid detection of 14 high risk and 6 low risk
human papillomavirus genotypes in cervical scrapings. J
Clin Microbiol 1997;3:791-5.
21 de Roda Husman AM, Snijders PJF, Stel HV, et al. Process-
ing of long-stored archival cervical smears for human pap-
illomavirus detection by the polymerase chain reaction. Br
J Cancer 1995;72:412-17.
22 Walboomers, JMM, Jacobs MV, Manos MM, et al. Human
papillomavirus is necessary cause of invasive cervical
cancer worldwide. J Pathol (in press).
23 Fleiss JL. Statistical methods for rates and proportions. New
York: John Wiley and Sons, 1981.
24 Jenkins D, Sherlaw-Johnson C, Gallivan S. Assessing the
role of HPV testing in cervical cancer screening. Papilloma-
virus Rep 1998;9:89-101.
25 Qu W, Jiang G, Cruz Y, et al. PCR detection of human
papillomavirus: comparison between MY09/11 and
GP5+/6+ primer systems.
_J Clin Microbiol 1997;35:1304-
10.
26 Nindl I, Jacobs MV, Walboomers JMM, et al. Interlabora-
tory agreement of different human papillomavirus DNA
detection and typing assays in cervical scrapes. Int_ Cancer1999:81:666-8.
27 Smits HL, Bollen LJM, Tjong-A-Hung SP, et al. Inter-
method variation in detection of human papillomavirus
DNA in cervical smears.
_J Clin Microbiol 1995;33:2631-6.
28 Ngelangel C, Mufioz N, Bosch FX, et al. The causes of cer-
vical cancer in the Philippines: a case-control study. Jf Natl
Cancer Inst 1998;90:50-7.
29 Chichareon S, Herrero R, Mudioz N, et al. Risk factors for
cervical cancer in Thailand: a case-control study.
_J Natl
Cancer Inst 1998;90:43-9.
503
